California State Teachers Retirement System lowered its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 9.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 56,190 shares of the medical device company’s stock after selling 5,716 shares during the period. California State Teachers Retirement System owned about 0.16% of AtriCure worth $1,363,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ATRC. Neuberger Berman Group LLC boosted its holdings in AtriCure by 45.5% in the second quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock valued at $19,993,000 after purchasing an additional 257,949 shares during the last quarter. FMR LLC boosted its holdings in AtriCure by 2.4% in the second quarter. FMR LLC now owns 5,068,247 shares of the medical device company’s stock valued at $122,905,000 after purchasing an additional 118,247 shares during the last quarter. Vanguard Group Inc. boosted its holdings in AtriCure by 5.7% in the first quarter. Vanguard Group Inc. now owns 1,393,971 shares of the medical device company’s stock valued at $26,695,000 after purchasing an additional 75,266 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in AtriCure in the second quarter valued at about $1,120,000. Finally, Royce & Associates LP boosted its holdings in AtriCure by 12.7% in the second quarter. Royce & Associates LP now owns 302,400 shares of the medical device company’s stock valued at $7,333,000 after purchasing an additional 34,100 shares during the last quarter. 87.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “California State Teachers Retirement System Has $1.36 Million Position in AtriCure, Inc. (ATRC)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/22/california-state-teachers-retirement-system-has-1-36-million-position-in-atricure-inc-atrc.html.

ATRC has been the topic of a number of research analyst reports. Zacks Investment Research raised AtriCure from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 target price on shares of AtriCure in a report on Monday, October 9th. Needham & Company LLC reduced their target price on AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $25.00 target price on shares of AtriCure in a report on Sunday, July 30th. Finally, ValuEngine downgraded AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. AtriCure presently has an average rating of “Hold” and a consensus target price of $25.00.

In related news, Director B Kristine Johnson purchased 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average price of $18.36 per share, with a total value of $27,540.00. Following the acquisition, the director now owns 10,969 shares in the company, valued at approximately $201,390.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 11.90% of the company’s stock.

AtriCure, Inc. (NASDAQ:ATRC) opened at $18.18 on Wednesday. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20. AtriCure, Inc. has a 1-year low of $14.78 and a 1-year high of $25.18.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.02. The business had revenue of $42.20 million for the quarter, compared to the consensus estimate of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The business’s revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.21) EPS. sell-side analysts anticipate that AtriCure, Inc. will post -0.96 earnings per share for the current year.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.